PI3K inhibitors exhibit frequent, dose-limiting toxicities including hyperglycemia (especially with PI3K-selective agents), rash, diarrhea/colitis, stomatitis, hepatotoxicity, and infections, with severity and spectrum varying by isoform selectivity [92,96,97,98,99,100,101]. This evidence concerns the gene PIK3CB and colitis.